Meeting
2018 ASCO Annual Meeting
A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer.
Authors
Arun Rajan
Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Arun Rajan , Julius Strauss , Alanvin Orpia , Margaret Elena Gatti-Mays , Eva Wagner , Christopher Ryan Heery , Cesar Pico , James L. Gulley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02840994
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9108)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9108
Abstract #
TPS9108
Poster Bd #
429a
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).
First Author: Guru Sonpavde
Poster
2024 ASCO Breakthrough
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.
First Author: Makoto Nishio
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok